Outcome Measures: |
Primary: Change from baseline in HbA1c at the end of treatment, at 24 weeks | Secondary: Change from baseline in Fasting plasma glucose at the end of treatment, at 24 weeks|Change from baseline in Fasting serum insulin at the end of treatment, at 24 weeks|Change from baseline in Body weight at the end of treatment, at 24 weeks|Change from baseline in Waist circumference at the end of treatment, at 24 weeks|Safety assessed by development of adverse events, vital signs, laboratory tests, and 12-lead ECG, ECG: Electrocardiogram, up to 24 weeks|Number of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit, at 4, 8, 12, 16 and 24 weeks|Percentage of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit, at 4, 8, 12, 16 and 24 weeks
|
Locations: |
Site KR00002, Busan, Korea, Republic of|Site KR00003, Busan, Korea, Republic of|Site KR00007, Daegu, Korea, Republic of|Site KR00011, Daegu, Korea, Republic of|Site KR00019, Dong Gu Gwangju, Korea, Republic of|Site KR00008, Gangwon-do, Korea, Republic of|Site KR00018, Gyeonggi-do, Korea, Republic of|Site KR00022, Gyeonggi-do, Korea, Republic of|Site KR00014, Incheon, Korea, Republic of|Site KR00020, Jeollabuk-do, Korea, Republic of|Site KR00021, Kyungsangnam-do, Korea, Republic of|Site KR00001, Seoul, Korea, Republic of|Site KR00004, Seoul, Korea, Republic of|Site KR00005, Seoul, Korea, Republic of|Site KR00006, Seoul, Korea, Republic of|Site KR00009, Seoul, Korea, Republic of|Site KR00010, Seoul, Korea, Republic of|Site KR00012, Seoul, Korea, Republic of|Site KR00013, Seoul, Korea, Republic of|Site KR00016, Seoul, Korea, Republic of|Site KR00017, Seoul, Korea, Republic of|Site KR00015, Suwon, Korea, Republic of
|